Related Experiment Video
Updated: Jan 20, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.9K
Hyponatraemia in heart failure
Su Ling Tee1, Andrew Sindone2, Simon Roger3
1Department of Cardiology, The Alfred, Melbourne, Victoria, Australia.
Internal Medicine Journal
|August 27, 2019
Summary
Hyponatraemia, or low sodium levels, is frequent in heart failure (HF) and indicates worse outcomes. This review explores its causes, consequences, and treatments in HF patients.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Hyponatraemia (low sodium) is prevalent in heart failure (HF), affecting over 20% of hospitalized patients.
- Low sodium levels in HF serve as a significant marker for increased patient morbidity and mortality.
- The neurohormonal dysregulation in HF contributes to the development of hyponatraemia.
Purpose of the Study:
- To review the pathophysiology of hyponatraemia in HF, focusing on neurohormonal activation.
- To discuss the clinical implications of persistent hyponatraemia in heart failure patients.
- To outline current and potential treatment strategies for hyponatraemia in the context of HF management.
Main Methods:
- Literature review of studies on hyponatraemia in heart failure.
- Analysis of pathophysiological mechanisms involving neurohormonal cascades.
- Synthesis of clinical data on morbidity, mortality, and treatment outcomes.
Main Results:
- Hyponatraemia arises from activated neurohormonal systems (e.g., renin-angiotensin-aldosterone, sympathetic nervous system, arginine vasopressin) in HF.
- Sustained low sodium levels are linked to prolonged hospital stays, increased readmissions, and higher mortality rates.
- Management strategies are evolving, with a focus on addressing underlying HF and specific hyponatraemia treatments.
Conclusions:
- Hyponatraemia is a critical complication of heart failure with significant prognostic implications.
- Understanding the neurohormonal basis of hyponatraemia is key to effective management.
- Further research and tailored therapeutic approaches are needed for optimal patient outcomes.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
768
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
720
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
01:22Heart Failure VI: Adjunct Therapies
273
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
273
01:22Heart Failure Drugs: Diuretics
821
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
821
01:30Heart Failure V: Medical Management
225
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
225